221 related articles for article (PubMed ID: 21960591)
41. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients.
Liu H; Chen P; Yang YL; Zhu KW; Wang T; Tang L; Liu YL; Cao S; Zhou G; Zeng H; Zhao XL; Zhang W; Chen XP
Eur J Pharmacol; 2021 Mar; 895():173894. PubMed ID: 33476656
[TBL] [Abstract][Full Text] [Related]
42. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract][Full Text] [Related]
43. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
44. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Gaidzik VI; Schlenk RF; Paschka P; Stölzle A; Späth D; Kuendgen A; von Lilienfeld-Toal M; Brugger W; Derigs HG; Kremers S; Greil R; Raghavachar A; Ringhoffer M; Salih HR; Wattad M; Kirchen HG; Runde V; Heil G; Petzer AL; Girschikofsky M; Heuser M; Kayser S; Goehring G; Teleanu MV; Schlegelberger B; Ganser A; Krauter J; Bullinger L; Döhner H; Döhner K
Blood; 2013 Jun; 121(23):4769-77. PubMed ID: 23632886
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
46. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
Gaidzik VI; Schlenk RF; Moschny S; Becker A; Bullinger L; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Döhner H; Döhner K;
Blood; 2009 May; 113(19):4505-11. PubMed ID: 19221039
[TBL] [Abstract][Full Text] [Related]
47. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
48. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
49. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Leuk Lymphoma; 2014 Jan; 55(1):110-20. PubMed ID: 23647058
[TBL] [Abstract][Full Text] [Related]
50. DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.
Sun GK; Tang LJ; Zhou JD; Xu ZJ; Yang L; Yuan Q; Ma JC; Liu XH; Lin J; Qian J; Yao DM
Cancer Med; 2019 Oct; 8(14):6393-6402. PubMed ID: 31486300
[TBL] [Abstract][Full Text] [Related]
51. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.
Ryotokuji T; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Kanda J; Kobayashi A; Omori I; Marumo A; Fujiwara Y; Yui S; Terada K; Fukunaga K; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Wakita S; Fukuda T; Inokuchi K
Haematologica; 2016 Sep; 101(9):1074-81. PubMed ID: 27247325
[TBL] [Abstract][Full Text] [Related]
52. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
[TBL] [Abstract][Full Text] [Related]
53. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
[TBL] [Abstract][Full Text] [Related]
54. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Damm F; Oberacker T; Thol F; Surdziel E; Wagner K; Chaturvedi A; Morgan M; Bomm K; Göhring G; Lübbert M; Kanz L; Fiedler W; Schlegelberger B; Heil G; Schlenk RF; Döhner K; Döhner H; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Feb; 29(6):682-9. PubMed ID: 21205756
[TBL] [Abstract][Full Text] [Related]
55. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
56. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
Damm F; Heuser M; Morgan M; Wagner K; Görlich K; Grosshennig A; Hamwi I; Thol F; Surdziel E; Fiedler W; Lübbert M; Kanz L; Reuter C; Heil G; Delwel R; Löwenberg B; Valk PJ; Krauter J; Ganser A
Blood; 2011 Apr; 117(17):4561-8. PubMed ID: 21372155
[TBL] [Abstract][Full Text] [Related]
57. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
[TBL] [Abstract][Full Text] [Related]
58. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
59. Bioinformatics Analysis to Determine Prognostic Mutations of 72 de novo Acute Myeloid Leukemia Cases from the Cancer Genome Atlas (TCGA) with 23 Most Common Mutations and no Abnormal Cytogenetics.
Welsh KJ; Nedelcu E; Wahed A; Bai Y; Dasgupta A; Nguyen A
Ann Clin Lab Sci; 2015; 45(5):515-21. PubMed ID: 26586702
[TBL] [Abstract][Full Text] [Related]
60.
Bai H; Zhou M; Zeng M; Han L
DNA Cell Biol; 2020 Apr; 39(4):700-708. PubMed ID: 32077754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
